NEW YORK (GenomeWeb) – With a CHF 1 million ($1.1 million) addition to its Series B financing round announced this week, Swiss proteomics firms ProteoMedix plans to begin clinical validation of its four-protein prostate cancer test.

The company will this year start clinical studies for the test in central Europe, the UK, and the US, enrolling a total of 1,500 patients, Co-founder and CEO Ralph Schiess told GenomeWeb. He added that ProteoMedix hopes to begin commercial roll-out of the test in the next two to three years, launching first in Europe and then in the US.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.

Jul
12
Sponsored by
Canon BioMedical

This webinar will discuss a project that is analyzing the “Human Brainome” – genome, transcriptome, proteome, and phenome interaction data -- to gain insights into Alzheimer’s disease pathogenesis.